# Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

> **NCT06683937** · — · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 300 (estimated)

## Conditions studied

- Immunocompromised Patients
- SARS-CoV-2 Disease

## Interventions

- **OTHER:** Collection of data from the patient's medical file

## Key facts

- **NCT ID:** NCT06683937
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683937, "Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06683937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*